Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2018 1
2019 4
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells.
De Vitis C, Corleone G, Salvati V, Ascenzi F, Pallocca M, De Nicola F, Fanciulli M, di Martino S, Bruschini S, Napoli C, Ricci A, Bassi M, Venuta F, Rendina EA, Ciliberto G, Mancini R. De Vitis C, et al. Among authors: salvati v. J Clin Med. 2019 Nov 9;8(11):1928. doi: 10.3390/jcm8111928. J Clin Med. 2019. PMID: 31717588 Free PMC article.
A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors.
Orienti I, Francescangeli F, De Angelis ML, Fecchi K, Bongiorno-Borbone L, Signore M, Peschiaroli A, Boe A, Bruselles A, Costantino A, Eramo A, Salvati V, Sette G, Contavalli P, Zolla L, Oki T, Kitamura T, Spada M, Giuliani A, Baiocchi M, La Torre F, Melino G, Tartaglia M, De Maria R, Zeuner A. Orienti I, et al. Among authors: salvati v. Cell Death Dis. 2019 Jul 23;10(7):529. doi: 10.1038/s41419-019-1775-y. Cell Death Dis. 2019. PMID: 31332161 Free PMC article.
A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.
Orienti I, Salvati V, Sette G, Zucchetti M, Bongiorno-Borbone L, Peschiaroli A, Zolla L, Francescangeli F, Ferrari M, Matteo C, Bello E, Di Virgilio A, Falchi M, De Angelis ML, Baiocchi M, Melino G, De Maria R, Zeuner A, Eramo A. Orienti I, et al. Among authors: salvati v. J Exp Clin Cancer Res. 2019 Aug 22;38(1):373. doi: 10.1186/s13046-019-1383-9. J Exp Clin Cancer Res. 2019. PMID: 31439019 Free PMC article.
ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin.
Ruggiero CF, Malpicci D, Fattore L, Madonna G, Vanella V, Mallardo D, Liguoro D, Salvati V, Capone M, Bedogni B, Ascierto PA, Mancini R, Ciliberto G. Ruggiero CF, et al. Among authors: salvati v. Cancers (Basel). 2019 Sep 25;11(10):1425. doi: 10.3390/cancers11101425. Cancers (Basel). 2019. PMID: 31557826 Free PMC article.
In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L, Campani V, Ruggiero CF, Salvati V, Liguoro D, Scotti L, Botti G, Ascierto PA, Mancini R, De Rosa G, Ciliberto G. Fattore L, et al. Among authors: salvati v. Int J Mol Sci. 2020 Mar 12;21(6):1930. doi: 10.3390/ijms21061930. Int J Mol Sci. 2020. PMID: 32178301 Free PMC article.
Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.
Sette G, Salvati V, Giordani I, Pilozzi E, Quacquarini D, Duranti E, De Nicola F, Pallocca M, Fanciulli M, Falchi M, Pallini R, De Maria R, Eramo A. Sette G, et al. Among authors: salvati v. Int J Cancer. 2018 Jul 1;143(1):88-99. doi: 10.1002/ijc.31260. Epub 2018 Jan 26. Int J Cancer. 2018. PMID: 29341112 Free article.
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.
Sette G, Fecchi K, Salvati V, Lotti F, Pilozzi E, Duranti E, Biffoni M, Pagliuca A, Martinetti D, Memeo L, Milella M, De Maria R, Eramo A. Sette G, et al. Among authors: salvati v. J Exp Clin Cancer Res. 2013 Nov 16;32(1):91. doi: 10.1186/1756-9966-32-91. J Exp Clin Cancer Res. 2013. PMID: 24238212 Free PMC article.